Updated:
Asymchem Laboratories (Tianjin)
Asymchem Laboratories (Tianjin) was established in 1998 by Hao Hong, who serves as chairman and CEO. The firm functions as a corporate investor and CDMO...
Asymchem Laboratories (Tianjin)
Asymchem Laboratories (Tianjin) was established in 1998 by Hao Hong, who serves as chairman and CEO. The firm functions as a corporate investor and CDMO focused on new drug development and manufacturing. Operations center on active pharmaceutical ingredient production and finished drug supply. Confirmed sites include headquarters in Tianjin plus facilities in Fuxin, Dunhua, Taixing, and the former Pfizer site in Sandwich, United Kingdom. Hillhouse Capital acts as a significant institutional investor. The company maintains a grantee relationship with the Bill & Melinda Gates Foundation. No recent operational events from the last 24 months appear in available records.
General information
Firm type
Corporate Investor
Year founded
1998
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Tianjin
Corporate office
No. 6 Dongting 3rd Avenue, TEDA, Tianjin, 300457, China
Additional offices
Fuxin, Liaoning, China · Dunhua, Jilin, China · Sandwich, Kent, United Kingdom · Taixing, Jiangsu, China
Principals
Hao Hong
Founder, Chairman, and CEO
Ye Song
Non-Executive Director
Sector focus
Frequently asked questions
Who runs investment decisions at Asymchem Laboratories (Tianjin)?
Hao Hong serves as founder, chairman, and CEO. Ye Song, his wife, holds a non-executive director role.
What is Asymchem Laboratories (Tianjin)'s primary business activity?
The firm operates as a CDMO engaged in the development and production of new drugs with manufacturing sites across China and the United Kingdom.
Which institutions hold stakes or partnerships with Asymchem Laboratories (Tianjin)?
Hillhouse Capital is a significant institutional investor. Merck & Co. and Pfizer maintain client and strategic relationships.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: